^
Association details:
| Biomarker: | KMT2D mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer
Published date:
01/05/2023
Excerpt:
Patients with KMT2C/D LOF benefited from ICIs in colorectal cancer in the MSKCC cohort….Overall, seven patients achieved partial response (PR), 14 patients achieved stable disease (SD), and seven patients achieved progressive disease (PD), resulting in an ORR rate of 25% (7/28). Among the 28 patients, 4 patients had KMT2C/D LOF mutations.
DOI:
https://doi.org/10.1111/cas.15716
Source:
Title:
Association of KMT2C/D loss-of-function mutations with tumor infiltrating lymphocytes and response to immune checkpoint inhibitors in solid tumors.
Published date:
05/19/2021
Excerpt:
...we explored the associations of KMT2C/D loss-of-function (LOF) mutations with the expression of immune-related genes, the levels of tumor infiltrating lymphocytes (TILs), and response to immune checkpoint inhibitors (ICIs)….The results showed that the predictive role of KMT2C/D LOF mutations for the clinical efficacy of ICIs therapy was only observed in colorectal cancer (P = 0.045).
DOI:
10.1200/JCO.2021.39.15_suppl.2587
Source:
Title:
1639 - Correlation of KMT2C/D loss-of-function mutations with PD-L1 expression and response to immune checkpoint inhibitors in solid tumors
Published date:
03/10/2021
Excerpt:
We classified the patients into two groups: KMT2C/D LOF (any truncating mutation) and non-LOF…. In MSKCC cohort, colorectal cancer patients in the LOF group had significantly longer median overall survival (OS) after ICIs therapy (34 vs 13 months, P = 0.0485)....Furthermore, KMT2C/D LOF mutations were also associated with better response to ICIs in colorectal cancer and NSCLC...
Source:
Title:
497P Investigating the potential relationship between KMT2C/KMT2D mutations and immune checkpoint inhibitor (ICI) in colorectal cancer (CRC)
Excerpt:
...the median OS differed widely (34 vs. 13 months) in KMT2C/2D MT and WT group (HR 0.46, 95% CI 0.24 to 0.88, p<0.05) ; the results supported that mutations in KMT2C/2D was associated with higher TMB and OS with ICI treatment.
DOI:
10.1016/j.annonc.2020.08.607
